Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис:
http://hdl.handle.net/20.500.12188/11817| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Cvetkovska, Emilija | en_US |
| dc.contributor.author | Kuzmanovski, I | en_US |
| dc.contributor.author | Babunovska, Marija | en_US |
| dc.contributor.author | Boshkovski, Bojan | en_US |
| dc.contributor.author | Aleksovska, Katina | en_US |
| dc.contributor.author | Trencevska Kiteva, Gordana | en_US |
| dc.date.accessioned | 2021-04-12T09:04:56Z | - |
| dc.date.available | 2021-04-12T09:04:56Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.uri | http://hdl.handle.net/20.500.12188/11817 | - |
| dc.description.abstract | The choice of antiepileptic drug is typically based on seizure type, and there is no evidence for superior effectiveness or potential deterioration of particular antiepileptic drug in specific etiologic subgroups. The aim of the study was to identify etiological factor(s) associated with increased risk of seizure aggravation with levetiracetam (LEV). | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Lippincott, Williams & Wilkins | en_US |
| dc.relation.ispartof | Clinical Neuropharmacology | en_US |
| dc.title | Levetiracetam-Induced Seizure Aggravation in Patients With Focal Cortical Dysplasia | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | 10.1097/WNF.0000000000000304 | - |
| dc.identifier.volume | 41 | - |
| dc.identifier.issue | 6 | - |
| item.fulltext | No Fulltext | - |
| item.grantfulltext | none | - |
| crisitem.author.dept | Faculty of Medicine | - |
| crisitem.author.dept | Faculty of Medicine | - |
| Appears in Collections: | Faculty of Medicine: Journal Articles | |
Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.